195 related articles for article (PubMed ID: 35976464)
21. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
[TBL] [Abstract][Full Text] [Related]
22. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
[TBL] [Abstract][Full Text] [Related]
23. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
25. Clinical and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single-center retrospective study.
Ning C; Zhang L; Zhao C; Chen X; Liu X; Gu C
J Int Med Res; 2021 Apr; 49(4):3000605211008065. PubMed ID: 33884911
[TBL] [Abstract][Full Text] [Related]
26. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
27. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): A retrospective study in a single center.
Zhang C; Gao J; Lu S; Zhang Y; Zhu H
Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():74-79. PubMed ID: 34467879
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound features of highly vascularized uterine myomas (uterine smooth muscle tumors) and correlation with histopathology.
Russo C; Camilli S; Martire FG; Di Giovanni A; Lazzeri L; Malzoni M; Zupi E; Exacoustos C
Ultrasound Obstet Gynecol; 2022 Aug; 60(2):269-276. PubMed ID: 35018681
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic evaluation of uterine smooth muscle tumors of uncertain malignant potential (STUMP): A single center experience.
Karataşlı V; Çakır İ; Ayaz D; Budak A; Sancı M
J Gynecol Obstet Hum Reprod; 2019 Oct; 48(8):637-642. PubMed ID: 30898630
[TBL] [Abstract][Full Text] [Related]
30. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
31. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
[TBL] [Abstract][Full Text] [Related]
32. A clinicopathologic study of uterine smooth muscle tumours of uncertain malignant potential (STUMP).
Ng JS; Han A; Chew SH; Low J
Ann Acad Med Singap; 2010 Aug; 39(8):625-8. PubMed ID: 20838704
[TBL] [Abstract][Full Text] [Related]
33. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.
Oduyebo T; Rauh-Hain AJ; Meserve EE; Seidman MA; Hinchcliff E; George S; Quade B; Nucci MR; Del Carmen MG; Muto MG
Gynecol Oncol; 2014 Feb; 132(2):360-5. PubMed ID: 24296345
[TBL] [Abstract][Full Text] [Related]
34. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
35. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
[TBL] [Abstract][Full Text] [Related]
36. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.
Dall'Asta A; Gizzo S; Musarò A; Quaranta M; Noventa M; Migliavacca C; Sozzi G; Monica M; Mautone D; Berretta R
Int J Clin Exp Pathol; 2014; 7(11):8136-42. PubMed ID: 25550862
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
38. ASO Author Reflections: Surgical Management and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): New Insights.
Borella F; Benedetto C; Cassoni P; Bertero L
Ann Surg Oncol; 2022 Dec; 29(13):8315-8316. PubMed ID: 35976463
[No Abstract] [Full Text] [Related]
39. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
40. Presurgical Identification of Uterine Smooth Muscle Malignancies through the Characteristic FDG Uptake Pattern on PET Scans.
Ho KC; Dean Fang YH; Lin G; Ueng SH; Wu TI; Lai CH; Chueh HY; Chao A; Chang TC; Yen TC
Contrast Media Mol Imaging; 2018; 2018():7890241. PubMed ID: 30018513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
